Ranirestat
Ranirestat (AS-3201) potent and orally active aldose reductase (AR) inhibitor with IC50s of 11 nM and 15 nM for rat lens AR and recombinant human AR, respectively, and a Ki of 0.38 nM for recombinant human AR. Ranirestat has the potential for diabetic sensorimotor polyneuropathy treatment. Ranirestat also has a neuroprotective effect on diabetic retinas[1][2].
Product Specifications
CAS Number
147254-64-6
Product Name Alternative
AS-3201
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
Aldose Reductase
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/Ranirestat.html
Concentration
10mM
Purity
98.0
Solubility
DMSO : ≥ 50 mg/mL
Smiles
O=C(N1CC2=CC=C(Br)C=C2F)C3=CC=CN3[C@]4(C(NC(C4)=O)=O)C1=O
Molecular Formula
C17H11BrFN3O4
Molecular Weight
420.19
Precautions
H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Lentiviral human ZMYM4 shRNA (UAS) - Lentiviral human ZMYM4 shRNA (UAS, iRFP) plasmid
Anti-Phospho-P53 (Ser37) Polyclonal Antibody 2
Anti-Phospho-P53 (Ser37) Polyclonal Antibody 2